Phibro Animal Health (NASDAQ:PAHC) Hits New 1-Year High - Still a Buy?

Key Points

• Stock hit a new 52‑week high — PAHC traded as high as $60.08 (last $59.58) on heavy volume, while its 50‑day/200‑day moving averages are $52.58/$44.68; analysts’ consensus is a Moderate Buy with an average price target of $37.50.
• Quarterly beat and upbeat guidance — Phibro reported $0.87 EPS vs. $0.69 expected and $373.9M revenue vs. $355.6M, and set FY2026 guidance of $2.93–3.10 EPS versus sell‑side forecasts around $1.95.
• Mixed insider/institutional activity — CEO Jack Bendheim sold 7,040 shares and insiders sold ~308,708 shares (~$15M) over 90 days, even as institutions like Millennium Management and JPMorgan materially increased stakes; the company also pays a $0.12 quarterly dividend (~0.8% yield).

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report)'s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $60.08 and last traded at $59.58, with a volume of 329401 shares trading hands. The stock had previously closed at $57.89.

Analysts Set New Price Targets

PAHC has been the subject of a number of recent analyst reports. Zacks Research upgraded Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a report on Wednesday, March 11th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Phibro Animal Health in a report on Monday, December 29th. Finally, Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $37.50.

Phibro Animal Health Stock Performance

The business has a fifty day simple moving average of $52.58 and a 200-day simple moving average of $44.68. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. The firm has a market cap of $2.42 billion, a P/E ratio of 26.48, a P/E/G ratio of 0.89 and a beta of 0.69.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.18. The business had revenue of $373.91 million during the quarter, compared to the consensus estimate of $355.64 million. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. On average, sell-side analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, March 25th. Stockholders of record on Wednesday, March 4th were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend was Wednesday, March 4th. Phibro Animal Health's dividend payout ratio is currently 21.33%.

Insider Activity at Phibro Animal Health

In other news, CEO Jack Bendheim sold 7,040 shares of the stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $52.52, for a total value of $369,740.80. Following the sale, the chief executive officer directly owned 73,320 shares of the company's stock, valued at approximately $3,850,766.40. This represents a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 308,708 shares of company stock valued at $14,952,409 over the last 90 days. Corporate insiders own 50.13% of the company's stock.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently modified their holdings of PAHC. Millennium Management LLC grew its stake in shares of Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company's stock worth $23,959,000 after acquiring an additional 626,492 shares during the last quarter. Capricorn Fund Managers Ltd purchased a new stake in shares of Phibro Animal Health in the third quarter worth $10,233,000. JPMorgan Chase & Co. grew its stake in shares of Phibro Animal Health by 1,730.9% in the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company's stock worth $9,634,000 after acquiring an additional 225,110 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Phibro Animal Health in the third quarter worth $8,931,000. Finally, Advisors Preferred LLC purchased a new stake in shares of Phibro Animal Health in the third quarter worth $3,953,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.